Boehringer Ingelheim announced Monday the opening of its new office in Jeddah. Expanding its presence in the Kingdom, this new office opening marks a major milestone in the long established partnership between Boehringer and Cigalah offering international quality therapies.
This milestone is another successful marker of Boehringer Ingelheim’s commitment to the Kingdom and the region.
Mohamed Bayoumy, Boehringer Ingelheim Country Head Saudi Arabia, said “we are delighted to be opening our new office in the Kingdom with our strategic partner Cigalah. Our plans for the Kingdom are and have always been ambitious. We are keen to provide innovative therapies to the Saudi market & we aim to play a bigger and meaningful role in servicing the patients.”
Bayoumy is optimistic that this will support or initiative of doubling Boehringer team by the end of the year. The increased demand, coupled with expected business growth and new launches of innovative Boehringer products in the Saudi market are key factors driving the team expansion in the company.
Dr. Abdel Aziz Al Serafy, CEO, Consultant of Cigalah Group said “this is a very exciting development for us. The health-care demands are growing in the country and we are eager to use our partnership to better serve the country. Our partnership started a long time ago as being Boehringer Ingelheim primary agent in the Kingdom and further strengthened with the company’s local secondary production; and now with this new office we have better reach to a wider network of Healthcare facilities and professionals”
The office was inaugurated by Dr. Abdel Aziz and Mohammed Al-Tawil, Boehringer Ingelheim General Manager NEMEA, in the presence of Mohamed Bayoumy, Boehringer Ingelheim Country Head, Saudi Arabia, and senior management team from both companies.
The growth of Saudi Arabia's economy over the past few years, the rapidly growing urban population and dramatic rise in conditions such as diabetes and obesity has fueled demands for more and better health care.
In 2015, the International Diabetes Federation reported there were 3.4 million patients in the Kingdom. The World Health Organization estimates heart conditions are linked to 24 percent of all deaths in the Kingdom and 55 percent of the Saudi population are predisposed to high cholesterol. Cancer is estimated to have reached 100 per 100,000 patients and is expected to rise at a growing rate.
Bayoumy added “our commitment to excellence and research into patient populations makes us confident that our medications will continue to earn the confidence of Health care professionals and patients alike in the years to come. We follow a focused strategy with three lines of therapies for cardiovascular, respiratory diseases and diabetes. This targeted approach gives us the capability to put our intelligence to use effectively and live up to our commitment”
Boehringer is especially committed to research into patient populations in order to improve understanding of conditions and patient experiences. — SG
